---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138954"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:13:47.425834+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics reports Q1 loss of $71.2M, VOWST approved, balance sheet strengthened with up to $250M facility

## Summary
- VOWST (fecal microbiota spores) FDA-approved for recurrent C. difficile; launch expected June 2023.
- Q1 net loss $71.2M vs $56.6M YoY; R&D $44.0M incl. $16M commercial manufacturing; cash $106.5M.
- Entered $250M debt facility with Oaktree; drew $110M (net ~$50M after retiring $53M debt).
- Due $125M milestone from Nestlé Health Science upon VOWST approval; pro-forma cash ~$282M.
- SER-155 Phase 1b Cohort 1 data: favorable tolerability, engraftment, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.

## SEC filing metadata
- accession: 0001193125-23-138954
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/0001193125-23-138954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/d456262d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138954
- JSON: https://secwatch.observer/filing/0001193125-23-138954.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138954.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported financial results for First Quarter 2023.
  - Period: First Quarter 2023
  - Result: reported results
  source text: Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312523138954/0001193125-23-138954-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.